Physician profile
Debora C Daniel
NPI 1023050614
$3,186.54
in general payments reported to CMS, 2019-2025
27 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $228 · 2021: $886 · 2022: $221 · 2023: $589 · 2024: $187 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $536.41 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $429.32 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $371.52 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $341.48 | 2021-2024 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $293.61 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $250.09 | 2021-2023 | |
| Gilead Sciences, INC. | $168.44 | 2019-2022 | |
| Lilly USA, LLC | $128.89 | 2022-2024 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $117.59 | 2021 | |
| Pfizer INC. | $71.72 | 2019-2024 | |
| Si-Bone, INC. | $65.27 | 2019 | |
| Axsome Therapeutics, INC. | $57.30 | 2025 | Auvelity |
| Abbott Laboratories | $42.31 | 2021-2023 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $35.89 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $30.99 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.65 | 2020-2021 | |
| Insulet Corporation | $24.23 | 2021 | |
| Corcept Therapeutics | $22.18 | 2025 | Korlym |
| Astellas Pharma US INC | $21.85 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $18.61 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $18.34 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.10 | 2024 | Voquezna |
| Merz North America, INC. | $17.50 | 2020 | |
| Dexcom, INC. | $16.32 | 2022 | |
| Esperion Therapeutics, INC. | $13.48 | 2021 | |
| Exact Sciences Corporation | $12.80 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.